Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN XR versus CYCLAPEN W.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN XR versus CYCLAPEN W.
AUGMENTIN XR vs CYCLAPEN-W
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin is a beta-lactam antibacterial that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamase enzymes, protecting amoxicillin from degradation.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has a similar spectrum to ampicillin but with increased acid stability and oral absorption.
Adults and adolescents ≥16 years: 2 tablets (amoxicillin 1000 mg/clavulanate 62.5 mg per tablet) orally every 12 hours for 10 days.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
Amoxicillin: ~1.0-1.3 hours; clavulanate: ~0.9-1.2 hours; prolonged in renal impairment (creatinine clearance <30 mL/min: amoxicillin half-life up to 7-14 hours).
0.5-1 hour in adults with normal renal function; prolonged to 2-6 hours in renal impairment.
Amoxicillin: ~50-70% excreted unchanged in urine via glomerular filtration and tubular secretion; clavulanate: ~25-40% excreted unchanged in urine; both undergo minor biliary/fecal elimination (<10%).
Primarily renal (90-100% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic